Aastrom Biosciences To Present at BMO Capital Markets Healthcare Conference

ANN ARBOR, Mich., Nov. 30  /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NASDAQ:ASTM), a clinical development stage company focused on the use of autologous cells for regenerative medicine, today announced that George W. Dunbar, President and Chief Executive Officer, and Elmar R. Burchardt, M.D., Ph.D., will present at the 2006 BMO Capital Markets Focus on Healthcare Conference.  The conference will be held December 6-7th at the Millennium Broadway Hotel in New York City.  Aastrom will present on Thursday, December 7, 2006 at 9:15 a.m. (Eastern Time).

(Logo:  http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO )

A live audio webcast of Aastrom's presentation can be accessed by logging onto the web at http://www.bmocm.com/conferences/healthcare2006 , and clicking on the "Audio Webcast" button.  A replay of the presentation will be archived until the conclusion of the conference on December 7th, at the same site.  For more information, please visit the conference website at http://www.bmocm.com/conferences/healthcare2006/default.aspx .

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NASDAQ:ASTM) is developing autologous cell products for the repair or regeneration of multiple human tissues, based on its proprietary Tissue Repair Cell (TRC) technology.  Aastrom's TRC-based products are a unique cell mixture containing stem and progenitor cell populations, produced from a small amount of bone marrow taken from the patient.  TRC-based products have been used in over 230 patients, and are currently in clinical trials for bone regeneration (long bone fractures and spine fusion) and vascular regeneration (critical limb ischemia) applications. Aastrom has reported positive interim clinical trial results for TRCs suggesting both the clinical safety and the ability of TRCs to promote healing in bone regeneration applications.  The Company's proprietary TRCs received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for use in the treatment of osteonecrosis of the femoral head.  In addition, Aastrom is developing plans for TRC-based therapies to address cardiac and neural regeneration indications.

For more information, visit Aastrom's website at http://www.aastrom.com/ .

This document contains forward-looking statements, including without limitation, statements regarding product development objectives, market development plans, and potential advantages and applications of Tissue Repair Cells, which involve certain risks and uncertainties.  The forward-looking statements are also identified through use of the words "plans," and other words of similar meaning.  Actual results may differ significantly from the expectations contained in the forward-looking statements.  Among the factors that may result in differences are the results obtained from clinical trial activities, regulatory approval requirements, and the availability of resources.  These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

  CONTACTS:  Kris M. Maly                       Cameron Associates
             Investor Relations Department      Kevin McGrath
             Aastrom Biosciences, Inc.          Phone: [phone]
             Phone: [phone]              Deanne Eagle (Media)
                                                Phone: [phone]


http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO

http://photoarchive.ap.org/

DATASOURCE: Aastrom Biosciences, Inc.



CONTACT:  Kris M. Maly, Investor Relations Department, Aastrom

Biosciences, Inc., [phone]; Cameron Associates: Kevin McGrath,

[phone], Deanne Eagle (Media), [phone]



Web site:  http://www.aastrom.com/

http://www.bmocm.com/conferences/healthcare2006

http://www.bmocm.com/conferences/healthcare2006/default.aspx 

Copyright